The Pharma Data

JANUARY 27, 2021

As a bioscience accelerator at the leading-edge of the life science industry, XPhyto targets growth through commercialization of its product pipeline and focused investment in impact driven innovation with the potential for meaningful value creation. . VANCOUVER, BC / ACCESSWIRE / January 28, 2021 / XPhyto Therapeutics Corp.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

Pharmaceutical Technology

APRIL 12, 2023

The ingredients used in these drugs are high potency, even at small doses, and pose a risk to both human health and cross-contamination with other drugs in a manufacturing environment. Currently mostly outsourced, there are signs that CMOs are beginning to make investments in containment capabilities, to capture emerging opportunities.

Manufacturing 130

Manufacturing Production Containment Contamination 130

Pharmaceutical Technology

JUNE 14, 2023

This, coupled with small pharma companies being unable to acquire or access containment capabilities in-house, means that the demand for innovative specialized small molecule capabilities remains high. Premium specialized equipment is necessary because high containment facilities call for the separation of the operator from the product.

Containment 130

Containment Manufacturing Contract Manufacturing Bioavailability 130